BURLINGTON, ON, Oct. 25 /CNW/ - The Jenex Corporation (TSX Venture
Exchange: JEN; Frankfurt: JNX -at Yahoo Finance, use JEN.V) announced that it
has been successful with the application for listing Therapik(R) as a medical
device and it is now cleared to launch in Australia.
The distributor, Felton Grimwade & Bickford Pty Ltd (FGB) of Oakleigh
South 3167, Australia will soon begin marketing Therapik(R) in Australia.
Jenex President Michael Jenkins commented: "We are pleased that the
Australian regulatory authorities have awarded approval for the sale of
Therapik(R) in so short a time. This additional approval will accelerate the
commercialization phase of our business. We believe FGB's market knowledge and
experience in Australia and New Zealand will help us meet and exceed our sales
targets for these markets."
Mike McKelvie, CEO of FGB says: "We plan to launch in Australia in
February. We look forward to distributing Therapik(R) to our many markets, as
a device to eliminate the pain and discomfort of insect bites and stings. It
is a product that would benefit every family."
About Felton Grimwade & Bickford Pty Ltd: FGB is an independent
Australian owned and operated natural products company. It manufactures and
markets a range of essential oils, O.T.C. pharmaceuticals, nutritional
supplements, household products, personal care products, and medical devices
in pharmacies and supermarkets throughout Australia, and in a growing number
of export markets. (www.fgb.com.au)
About The Jenex Corporation: Jenex has a non-invasive Medical Device that
prevents cold sore outbreaks. The interceptCS(TM) Cold Sore Prevention System
is approved in Canada and has received CE approval for European Union
countries. In addition to interceptCS, Jenex markets Therapik(R) for insect
stings & bites. Therapik(R) immediately relieves the pain & itch caused by
over 20,000 different insects. Therapik(R) is approved in Canada and the
United States and Australia, as well as having CE Mark approval in the
European Union countries.
Jenex's Thermal Therapy technology is patented in the U.S., Canada,
Australia, & Europe.
Check www.interceptCS.com and www.JenexCorp.com for details.
The TSX Venture Exchange Inc. has not reviewed and does not accept
responsibility for the accuracy or the contents of this press release.
Certain information included in this press release is forward-looking and
is subject to important risks and uncertainties. The results or events
predicted in these statements may differ materially from actual results
For further information:
For further information: The Jenex Corporation, Michael A. Jenkins,
(905) 632-3830, email@example.com